Lonza to manufacture Acumen’s monoclonal antibody, sabirnetug , for clinical development and commercialization, if approvedSabirnetug is the first monoclonal antibody candidate to enter the clinic.
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer s Disease tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.